Ki-20227
Compound status:
Historic compound: While this compound has been used to interrogate specific protein targets, it is not a chemical probe and should not be used in assays that depend on a potent and selective modulator of the protein.Note about activity:
Intended target CSF1R; Available data reveal limited profiling against kinases, and insufficient evidence to establish that this compound is acting on the intended target in cells; Ohno et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 5, 2634-43 (2006).
